Bayer taps Iambic's AI platform (Enchant & NeuralPLexer) for small molecule drug discovery

Bayer has entered a partnership with Iambic Therapeutics to leverage its AI-driven drug discovery platform for small molecule development. The collaboration, announced on June 23, 2026, focuses on using Iambic's flagship technologies: Enchant, which rapidly designs potent and selective molecular starting points, and NeuralPLexer, a deep learning model that predicts ligand-protein binding structures with exceptional accuracy. These tools enable Bayer to tackle 'hard-to-drug' targets—proteins that resist traditional drug design due to challenging binding sites or structural complexity.

By integrating Iambic's platform, Bayer aims to accelerate the identification of novel drug entry points and create differentiated molecules with better safety and efficacy profiles. The partnership strengthens Bayer's R&D portfolio, particularly in therapeutic areas where conventional approaches have stalled. Iambic's AI system can explore vast chemical spaces and predict how potential drugs interact with their targets, reducing the time and cost of early-stage discovery. For Bayer, this means faster progression from target identification to lead optimization, potentially bringing new treatments to patients sooner. The collaboration underscores the growing trend of pharma giants adopting specialized AI platforms to overcome bottlenecks in drug discovery.